Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vyome Holdings Inc (HIND)

Vyome Holdings Inc (HIND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,973
  • Shares Outstanding, K 5,644
  • Annual Sales, $ 8,010 K
  • Annual Income, $ -7,130 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.21
  • Price/Sales 2.89
  • Price/Cash Flow N/A
  • Price/Book 3.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.89 +2.97%
on 12/17/25
5.88 -31.88%
on 12/08/25
-0.87 (-17.92%)
since 11/17/25
3-Month
3.89 +2.97%
on 12/17/25
6.63 -39.58%
on 09/19/25
-2.31 (-36.62%)
since 09/17/25
52-Week
3.89 +2.97%
on 12/17/25
519.00 -99.23%
on 01/13/25
-454.99 (-99.13%)
since 12/17/24

Most Recent Stories

More News
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002). ...

HIND : 4.01 (-1.58%)
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Dr. Bardia has led the clinical development and FDA approvals of multiple blockbuster drugs

HIND : 4.01 (-1.58%)
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

(Quarter Ended September 30, 2025) Completed a streamlined Nasdaq listing, with a 100% common stock capital structure ...

HIND : 4.01 (-1.58%)
Vyome Holdings Announces Results of Annual Shareholder Meeting

All 3 Class I directors, formerly at MIT, are re-elected to the board until the 2028 annual meeting

HIND : 4.01 (-1.58%)
Vyome Holdings Acquires AI Startup Oculo, Inc.

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vyome Holdings...

HIND : 4.01 (-1.58%)
Vyome Holdings Acquires MIT AI Spinout Oculo Health

Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets

HIND : 4.01 (-1.58%)
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome’s offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 eyedrop achieves the desired concentration in the...

HIND : 4.01 (-1.58%)
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Dr. Richard Fahrner and Dr. Tamara Agajanov add expertise in accelerated approvals

HIND : 4.01 (-1.58%)
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

VT-1953 continues to significantly improve the primary endpoint Co-founder Dr. Shiladitya Sengupta to discuss over a live video conference ...

HIND : 4.01 (-1.58%)
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio

Vyome seeks to access multi-billion-dollar AI-enabled medical device market

HIND : 4.01 (-1.58%)

Business Summary

Vyome Therapeutics Inc. is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases principally in the US. Vyome Therapeutics Inc., formerly known as ReShape Lifesciences Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.61
2nd Resistance Point 4.48
1st Resistance Point 4.28
Last Price 4.01
1st Support Level 3.95
2nd Support Level 3.82
3rd Support Level 3.62

See More

52-Week High 519.00
Fibonacci 61.8% 322.23
Fibonacci 50% 261.45
Fibonacci 38.2% 200.66
Last Price 4.01
52-Week Low 3.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar